Externally Partnered Pipeline

Our partnered pipeline includes drug candidates that we have out licensed to leading pharmaceutical and biotechnology companies, including Boehringer Ingelheim, Genmab and Zymeworks.

Our partners are developing one or more drug candidates that we discovered using our OGAP® platform.

​

Program	Program Summary	Indications	Molecule Class
OBT620	A DLL3/CD3 bispecific molecule to treat patients with small cell lung cancer and other neuroendocrine tumors that are positive for DLL3. Currently in phase I clinical trial.	​SCLC and neuroendocrine tumors	CD3 bispecific
OBT624	A B7-H6/CD3 bispecific molecule to treat patients with advanced solid tumors.	Advanced solid tumors​	CD3 bispecific
OBT551	Undisclosed molecule in pre-clinical development.	Solid tumors	Undisclosed
Four programs	Four programs enabled by OBT's OGAP® discovery platform are undergoing validation.	Solid tumors	Undisclosed
OBT700	A novel, first-in-class, immune checkpoint receptor agonist discovered and developed by OBT.	Solid tumors​	IO mAB
Undisclosed	Novel, first-in-class antibody therapeutics.​	Solid tumors​​	Undisclosed

IO mAB: Immuno-oncology monoclonal antibody.